Tempest Therapeutics, Inc.: Business Overview, Financials & Competitive Analysis
Tempest Therapeutics, Inc. scores 6/10 on the AskCyborg Cyborg Score (Solid). Clinical-stage biotech with differentiated small molecule approach, strong partnership validation, and pipeline expansion positioning it for mid-stage catalysts. Tempest demonstrates solid fundamentals with a lead program showing clinical activity, strategic partnerships with Roche, recent pipeline expansion through CAR-T acquisition, and analyst support (average rating: Buy with $10.0 price target.
What is Tempest Therapeutics, Inc.'s industry? Tempest Therapeutics, Inc. (tempesttx.com) operates in Oncology/Immuno-Oncology - Clinical Stage Biotechnology. AskCyborg classifies Tempest Therapeutics, Inc. under Oncology/Immuno-Oncology - Clinical Stage Biotechnology in its company registry.
Tempest Therapeutics is a clinical-stage oncology company developing first-in-class small molecule therapeutics that combine tumor-targeted and immune-mediated mechanisms to treat cancer. The company's lead program, A...
Cyborg Score thesis
Clinical-stage biotech with differentiated small molecule approach, strong partnership validation, and pipeline expansion...
Read the full analyst-debate transcript →Get the Latest Tempest Therapeutics, Inc. Report
Up-to-date AI-powered research, analyst debate audio & saved-company playlists
Get Current Report FreeTempest Therapeutics, Inc. Overview
Pro stress-test →Tempest Therapeutics is a clinical-stage oncology company developing first-in-class small molecule therapeutics that combine tumor-targeted and immune-mediated mechanisms to treat cancer. The company's lead program, Amezalpat (TPST-1120), is advancing in a pivotal Phase 1b/2 study in collaboration with Roche for hepatocellular carcinoma and has demonstrated clinical activity across multiple cancer types.
Strategic Profile
Pro stress-test →Tempest differentiates through dual-mechanism small molecules designed to activate both tumor killing and immune responses, partnering with pharmaceutical leaders like Roche to de-risk development. The company recently acquired dual-targeting CAR-T programs from Factor Bioscience to expand its pipeline and extend runway while maintaining a capital-efficient strategy with partner-funded programs.
Competitive Landscape
Pro stress-test →Tempest competes in the oncology space against both large pharma and clinical-stage biotech developers. Direct competitors include other immuno-oncology and small molecule cancer therapy companies, but Tempest's differentiation lies in its dual tumor-targeted and immune-mediated mechanism approach combined with validation from Roche partnership, positioning it as a focused player in the competitive immuno-oncology landscape.
Industry Context
Tempest Therapeutics, Inc. operates in Oncology/Immuno-Oncology - Clinical Stage Biotechnology.
Key facts
Founded: 2011 · Headquarters: Brisbane, CA, United States